Tracy Robson

Tracy Robson

Head of Department

Tracy Robson obtained her PhD in Cancer Biology from Imperial College, London. Her first academic post was as Lecturer in Radiation Science at Ulster University in 1997; she was promoted to Reader in 2001. She then moved to the School of Pharmacy, Queen’s University of Belfast in 2004 to take up the post of Reader in Molecular Pharmacology; she was promoted to Professor in 2010. In 2016, she took up position as Professor and Head of Department of Molecular and Cellular Therapeutics at RCSI. Her major focus has been in the tumour biology field.  She led a major programme of research aimed at the identification and functional characterisation of genes that alter tumour biology.  In particular, she cloned and characterized a novel human gene, FKBPL. Her group has demonstrated that FKBPL was a naturally secreted, anti-angiogenic protein. Together with Almac Discovery, she led the development of therapeutic peptide derivatives (AD-01 and ALM201) based on FKBPL’s active anti-angiogenic domain. Based on the robust efficacy and excellent safety profile, ALM201, a ‘first-in-class’ FKBPL-based anti-angiogenic therapeutic peptide has successfully completed a phase I cancer clinical trial (EudraCT number: 2014-001175-31).  ALM201 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) in the treatment of ovarian cancer in 2017. More recently, through the development of genetically modified mouse models, she demonstrated a role for FKBPL in protection against obesity, with FKBPL deficient mice becoming severely obese. Her research is now focussing on unravelling the associated mechanisms driving FKBPL’s protective activity in obesity (as well as cancer) so that the clear translational potential of FKBPL-based therapeutics can be fully harnessed and FKBPL’s diagnostic potential in these disease settings can be utililized.

Tracy Robson

Head of Department

Dr. Stephanie Annett
Position: Postdoctoral Researcher & Honorary Lecturer

Stephanie is a post doctoral scientist, funded by NCRC and is conducting research on FKBPL’s role in childhood obesity.

Dr. Gillian Moore
Position: Postdoctoral Researcher

Gillian is a postdoctoral researcher investigating the anti-cancer activity of FKBPL and drug peptide derivatives. She is funded by Almac Discovery.

Unravelling the role of FKBPL in Childhood Obesity

Amongst Irish children, there has been a dramatic two-to-four fold increase in obesity since 1990; 1 in 5 Irish children are now obese. As these children grow into obese adults, they are seven times more likely to become a type 2 diabetic or develop heart disease and cancer. To further investigate the biology underlying obesity in children, we have identified a novel role for a specific protein, called FKBPL, which regulates blood vessels that can feed fat. Low levels of this protein also appear to promote fat development and stimulate immune cells exacerbating the problem. We will investigate how FKBPL influences obese pathology with a view to providing new diagnostic and treatment options for these children. Our co-investigators include: Dr Annie Curtis (RCSI) and Prof Declan Cody (OLCHC) and Dr Andrew Hogan (NCRC and Maynooth),

The list of publications below is automatically derived from MEDLINE/PubMed. As a result, there may be incorrect or missing publications.

Annett S, Moore G, Robson T, 2020 Jul 2, FK506 binding proteins and inflammation related signalling pathways; basic biology, current status and future prospects for pharmacological intervention. Pharmacol Ther, DOI: 10.1016/j.pharmthera.2020.107623
Todd N, McNally R, Alqudah A, Jerotic D, Suvakov S, Obradovic D, Hoch D, Hombrebueno JR, Campos GL, Watson CJ, Gojnic-Dugalic M, Simic TP, Kransodembskaya A, Desoye G, Eastwood KA, Hunter AJ, Holmes VA, McCance DR, Young IS, Grieve DJ, Kenny LC, Garovic VD, Robson T, McClements L, 2020 Jul 3, Role of a novel angiogenesis FKBPL-CD44 pathway in preeclampsia risk stratification and mesenchymal stem cell treatment. J Clin Endocrinol Metab, DOI: 10.1210/clinem/dgaa403
Moore G, Annett S, McClements L, Robson T, 2020 Jun 20, Top Notch Targeting Strategies in Cancer: A Detailed Overview of Recent Insights and Current Perspectives. Cells, DOI: 10.3390/cells9061503
Bernhard GH, Neale RE, Barnes PW, Neale PJ, Zepp RG, Wilson SR, Andrady AL, Bais AF, McKenzie RL, Aucamp PJ, Young PJ, Liley JB, Lucas RM, Yazar S, Rhodes LE, Byrne SN, Hollestein LM, Olsen CM, Young AR, Robson TM, Bornman JF, Jansen MAK, Robinson SA, Ballaré CL, Williamson CE, Rose KC, Banaszak AT, Häder DP, Hylander S, Wängberg SÅ, Austin AT, Hou WC, Paul ND, Madronich S, Sulzberger B, Solomon KR, Li H, Schikowski T, Longstreth J, Pandey KK, Heikkilä AM, White CC, 2020 May 20, Environmental effects of stratospheric ozone depletion, UV radiation and interactions with climate change: UNEP Environmental Effects Assessment Panel, update 2019. Photochem Photobiol Sci, DOI: 10.1039/d0pp90011g
Annett S, Moore G, Short A, Marshall A, McCrudden C, Yakkundi A, Das S, McCluggage WG, Nelson L, Harley I, Moustafa N, Kennedy CJ, deFazio A, Brand A, Sharma R, Brennan D, O'Toole S, O'Leary J, Bates M, O'Riain C, O'Connor D, Furlong F, McCarthy H, Kissenpfennig A, McClements L, Robson T, 2020 Feb, FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer. Br J Cancer, DOI: 10.1038/s41416-019-0649-5
Mulholland EJ, Ali A, Robson T, Dunne NJ, McCarthy HO, 2019 Dec 28, Delivery of RALA/siFKBPL nanoparticles via electrospun bilayer nanofibres: An innovative angiogenic therapy for wound repair. J Control Release, DOI: 10.1016/j.jconrel.2019.10.050
Pieristè M, Chauvat M, Kotilainen TK, Jones AG, Aubert M, Robson TM, Forey E, 2019 Sep, Solar UV-A radiation and blue light enhance tree leaf litter decomposition in a temperate forest. Oecologia, DOI: 10.1007/s00442-019-04478-x
Cole G, Ali AA, McErlean E, Mulholland EJ, Short A, McCrudden CM, McCaffrey J, Robson T, Kett VL, Coulter JA, Dunne NJ, Donnelly RF, McCarthy HO, 2019 Sep 15, DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen. Acta Biomater, DOI: 10.1016/j.actbio.2019.07.003
McClements L, Annett S, Yakkundi A, O'Rourke M, Valentine A, Moustafa N, Alqudah A, Simões BM, Furlong F, Short A, McIntosh SA, McCarthy HO, Clarke RB, Robson T, 2019 Apr 11, FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4. BMC Cancer, DOI: 10.1186/s12885-019-5500-0
Bornman JF, Barnes PW, Robson TM, Robinson SA, Jansen MAK, Ballaré CL, Flint SD, 2019 Mar 1, Linkages between stratospheric ozone, UV radiation and climate change and their implications for terrestrial ecosystems. Photochem Photobiol Sci, DOI: 10.1039/c8pp90061b
McCrudden CM, McBride JW, McCaffrey J, McErlean EM, Dunne NJ, Kett VL, Coulter JA, Robson T, McCarthy HO, 2018, Gene therapy with RALA/iNOS composite nanoparticles significantly enhances survival in a model of metastatic prostate cancer. Cancer Nanotechnol, DOI: 10.1186/s12645-018-0040-x
Cole G, Ali AA, McCrudden CM, McBride JW, McCaffrey J, Robson T, Kett VL, Dunne NJ, Donnelly RF, McCarthy HO, 2018 Jun, DNA vaccination for cervical cancer: Strategic optimisation of RALA mediated gene delivery from a biodegradable microneedle system. Eur J Pharm Biopharm, DOI: 10.1016/j.ejpb.2018.02.029
Byrne T, Nelson L, Beirne JP, Sharpe D, Quinn JE, McCluggage WG, Robson T, Furlong F, 2018 Mar, BRCA1 and MAD2 Are Coexpressed and Are Prognostic Indicators in Tubo-ovarian High-Grade Serous Carcinoma. Int J Gynecol Cancer, DOI: 10.1097/IGC.0000000000001214
Annett S, Robson T, 2018 Jul, Targeting cancer stem cells in the clinic: Current status and perspectives. Pharmacol Ther, DOI: 10.1016/j.pharmthera.2018.02.001
O'Sullivan JM, Preston RJS, Robson T, O'Donnell JS, 2018 Mar, Emerging Roles for von Willebrand Factor in Cancer Cell Biology. Semin Thromb Hemost, DOI: 10.1055/s-0037-1607352
McCrudden CM, McBride JW, McCaffrey J, Ali AA, Dunne NJ, Kett VL, Coulter JA, Robson T, McCarthy HO, 2017 Mar 17, Systemic RALA/iNOS Nanoparticles: A Potent Gene Therapy for Metastatic Breast Cancer Coupled as a Biomarker of Treatment. Mol Ther Nucleic Acids, DOI: 10.1016/j.omtn.2016.12.010
Ali AA, McCrudden CM, McCaffrey J, McBride JW, Cole G, Dunne NJ, Robson T, Kissenpfennig A, Donnelly RF, McCarthy HO, 2017 Apr, DNA vaccination for cervical cancer; a novel technology platform of RALA mediated gene delivery via polymeric microneedles. Nanomedicine, DOI: 10.1016/j.nano.2016.11.019
Massey AS, Pentlavalli S, Cunningham R, McCrudden CM, McErlean EM, Redpath P, Ali AA, Annett S, McBride JW, McCaffrey J, Robson T, Migaud ME, McCarthy HO, 2016 Apr 4, Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA. Mol Pharm, DOI: 10.1021/acs.molpharmaceut.5b00670
McCaffrey J, McCrudden CM, Ali AA, Massey AS, McBride JW, McCrudden MT, Vicente-Perez EM, Coulter JA, Robson T, Donnelly RF, McCarthy HO, 2016 Mar 28, Transcending epithelial and intracellular biological barriers; a prototype DNA delivery device. J Control Release, DOI: 10.1016/j.jconrel.2016.02.023
McBride JW, Massey AS, McCaffrey J, McCrudden CM, Coulter JA, Dunne NJ, Robson T, McCarthy HO, 2016 Mar 16, Development of TMTP-1 targeted designer biopolymers for gene delivery to prostate cancer. Int J Pharm, DOI: 10.1016/j.ijpharm.2016.01.039
Armstrong CW, Maxwell PJ, Ong CW, Redmond KM, McCann C, Neisen J, Ward GA, Chessari G, Johnson C, Crawford NT, LaBonte MJ, Prise KM, Robson T, Salto-Tellez M, Longley DB, Waugh DJ, 2016 Feb 16, PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy. Oncotarget, DOI: 10.18632/oncotarget.6955
Lawler M, Gavin A, Salto-Tellez M, Kennedy RD, Van Schaeybroeck S, Wilson RH, Harkin DP, Grayson M, Boyd RE, Hamilton PW, McArt DG, James J, Robson T, Ladner RD, Prise KM, O'Sullivan JM, Harrison T, Murray L, Johnston PG, Waugh DJ, 2016 Mar 1, Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program. Cancer, DOI: 10.1002/cncr.29814
Duffy SW, Dibden A, Michalopoulos D, Offman J, Parmar D, Jenkins J, Collins B, Robson T, Scorfield S, Green K, Hall C, Liao XH, Ryan M, Johnson F, Stevens G, Kearins O, Sellars S, Patnick J, 2016 Jan, Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study. Lancet Oncol, DOI: 10.1016/S1470-2045(15)00446-5
Bennett R, Yakkundi A, McKeen HD, McClements L, McKeogh TJ, McCrudden CM, Arthur K, Robson T, McCarthy HO, 2015 Oct, RALA-mediated delivery of FKBPL nucleic acid therapeutics. Nanomedicine (Lond), DOI: 10.2217/nnm.15.115
McClements L, Annett S, Yakkundi A, Robson T, 2015, The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases. Curr Mol Pharmacol, DOI: 10.2174/1874467208666150519115729
Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirström K, Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T, 2015 May 20, FKBPL: a marker of good prognosis in breast cancer. Oncotarget, DOI: 10.18632/oncotarget.3528
Jack RH, Robson T, Davies EA, 2016 Jun, The varying influence of socioeconomic deprivation on breast cancer screening uptake in London. J Public Health (Oxf), DOI: 10.1093/pubmed/fdv038
Yakkundi A, Bennett R, Hernández-Negrete I, Delalande JM, Hanna M, Lyubomska O, Arthur K, Short A, McKeen H, Nelson L, McCrudden CM, McNally R, McClements L, McCarthy HO, Burns AJ, Bicknell R, Kissenpfennig A, Robson T, 2015 Apr, FKBPL is a critical antiangiogenic regulator of developmental and pathological angiogenesis. Arterioscler Thromb Vasc Biol, DOI: 10.1161/ATVBAHA.114.304539
Klem K, Holub P, Štroch M, Nezval J, Špunda V, Tříska J, Jansen MA, Robson TM, Urban O, 2015 Aug, Ultraviolet and photosynthetically active radiation can both induce photoprotective capacity allowing barley to overcome high radiation stress. Plant Physiol Biochem, DOI: 10.1016/j.plaphy.2015.01.001
Jack RH, Møller H, Robson T, Davies EA, 2014 Oct 16, Breast cancer screening uptake among women from different ethnic groups in London: a population-based cohort study. BMJ Open, DOI: 10.1136/bmjopen-2014-005586
McCarthy HO, McCaffrey J, McCrudden CM, Zholobenko A, Ali AA, McBride JW, Massey AS, Pentlavalli S, Chen KH, Cole G, Loughran SP, Dunne NJ, Donnelly RF, Kett VL, Robson T, 2014 Sep 10, Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery. J Control Release, DOI: 10.1016/j.jconrel.2014.06.048
Robson TC, Braungardt CB, Rieuwerts J, Worsfold P, 2014 Jan, Cadmium contamination of agricultural soils and crops resulting from sphalerite weathering. Environ Pollut, DOI: 10.1016/j.envpol.2013.09.001
Donley C, McClelland K, McKeen HD, Nelson L, Yakkundi A, Jithesh PV, Burrows J, McClements L, Valentine A, Prise KM, McCarthy HO, Robson T, 2014 Jun 26, Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen. Oncogene, DOI: 10.1038/onc.2013.306
McClements L, Yakkundi A, Papaspyropoulos A, Harrison H, Ablett MP, Jithesh PV, McKeen HD, Bennett R, Donley C, Kissenpfennig A, McIntosh S, McCarthy HO, O'Neill E, Clarke RB, Robson T, 2013 Jul 15, Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway. Clin Cancer Res, DOI: 10.1158/1078-0432.CCR-13-0595
Yakkundi A, McCallum L, O'Kane A, Dyer H, Worthington J, McKeen HD, McClements L, Elliott C, McCarthy HO, Hirst DG, Robson T, 2013, The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway. PLoS One, DOI: 10.1371/journal.pone.0055075
Ali AA, Coulter JA, Ogle CH, Migaud MM, Hirst DG, Robson T, McCarthy HO, 2013 Mar 28, The contribution of N₂O₃ to the cytotoxicity of the nitric oxide donor DETA/NO: an emerging role for S-nitrosylation. Biosci Rep, DOI: 10.1042/BSR20120120
McCluskey AG, Mairs RJ, Sorensen A, Robson T, McCarthy HO, Pimlott SL, Babich JW, Champion S, Boyd M, 2013 Mar, Gamma irradiation and targeted radionuclides enhance the expression of the noradrenaline transporter transgene controlled by the radio-inducible p21(WAF1/CIP1) promoter. Radiat Res, DOI: 10.1667/RR3030.1
Song L, Robson T, Doig T, Brenn T, Mathers M, Brown ER, Doherty V, Bartlett JM, Anderson N, Melton DW, 2013 Jan, DNA repair and replication proteins as prognostic markers in melanoma. Histopathology, DOI: 10.1111/j.1365-2559.2012.04362.x
Robson T, James IF, 2012 Jun, The therapeutic and diagnostic potential of FKBPL; a novel anticancer protein. Drug Discov Today, DOI: 10.1016/j.drudis.2012.01.002
McKeen HD, Brennan DJ, Hegarty S, Lanigan F, Jirstrom K, Byrne C, Yakkundi A, McCarthy HO, Gallagher WM, Robson T, 2011 Apr, The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL. Biochem Soc Trans, DOI: 10.1042/BST0390663
Bartlett JM, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ET, Kay C, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix L, Seynaeve C, Rea D, 2011 Apr 20, Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol, DOI: 10.1200/JCO.2010.30.3677
Valentine A, O'Rourke M, Yakkundi A, Worthington J, Hookham M, Bicknell R, McCarthy HO, McClelland K, McCallum L, Dyer H, McKeen H, Waugh DJ, Roberts J, McGregor J, Cotton G, James I, Harrison T, Hirst DG, Robson T, 2011 Mar 1, FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism. Clin Cancer Res, DOI: 10.1158/1078-0432.CCR-10-2241
Hirst DG, Robson T, 2011, Nitric oxide physiology and pathology. Methods Mol Biol, DOI: 10.1007/978-1-61737-964-2_1
McCarthy HO, Zholobenko AV, Wang Y, Canine B, Robson T, Hirst DG, Hatefi A, 2011 Feb 28, Evaluation of a multi-functional nanocarrier for targeted breast cancer iNOS gene therapy. Int J Pharm, DOI: 10.1016/j.ijpharm.2010.11.051
Coulter JA, Page NL, Worthington J, Robson T, Hirst DG, McCarthy HO, 2010 Sep, Transcriptional regulation of inducible nitric oxide synthase gene therapy: targeting early stage and advanced prostate cancer. J Gene Med, DOI: 10.1002/jgm.1495
Robson T, West C, 2010 Aug, Radiation and the genome: from risks to opportunities for therapeutic exploitation. Br J Radiol, DOI: 10.1259/bjr/31552255
Hirst D, Robson T, 2010, Nitric oxide in cancer therapeutics: interaction with cytotoxic chemotherapy. Curr Pharm Des, DOI: 10.2174/138161210790232185
Hirst DG, Robson T, 2010 Jan, Nitrosative stress as a mediator of apoptosis: implications for cancer therapy. Curr Pharm Des, DOI: 10.2174/138161210789941838
Sunnotel O, Hiripi L, Lagan K, McDaid JR, De León JM, Miyagawa Y, Crowe H, Kaluskar S, Ward M, Scullion C, Campbell A, Downes CS, Hirst D, Barton D, Mocanu E, Tsujimura A, Cox MB, Robson T, Walsh CP, 2010 Mar 8, Alterations in the steroid hormone receptor co-chaperone FKBPL are associated with male infertility: a case-control study. Reprod Biol Endocrinol, DOI: 10.1186/1477-7827-8-22
McKeen HD, Byrne C, Jithesh PV, Donley C, Valentine A, Yakkundi A, O'Rourke M, Swanton C, McCarthy HO, Hirst DG, Robson T, 2010 Feb 1, FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy. Cancer Res, DOI: 10.1158/0008-5472.CAN-09-2515
Faratian D, Kay C, Robson T, Campbell FM, Grant M, Rea D, Bartlett JM, 2009 Nov, Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the TEAM Trial Experience. Histopathology, DOI: 10.1111/j.1365-2559.2009.03419.x
Devlin AH, Thompson P, Robson T, McKeown SR, 2010 Feb, Cytochrome P450 1B1 mRNA untranslated regions interact to inhibit protein translation. Mol Carcinog, DOI: 10.1002/mc.20589
Ali M, Telfer BA, McCrudden C, O'Rourke M, Thomas HD, Kamjoo M, Kyle S, Robson T, Shaw C, Hirst DG, Curtin NJ, Williams KJ, 2009 Oct 1, Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clin Cancer Res, DOI: 10.1158/1078-0432.CCR-09-0398
Coleman MR, Davis MH, Rodd JM, Robson T, Ali A, Owen AM, Pickard JD, 2009 Sep, Towards the routine use of brain imaging to aid the clinical diagnosis of disorders of consciousness. Brain, DOI: 10.1093/brain/awp183
Adams C, McCarthy HO, Coulter JA, Worthington J, Murphy C, Robson T, Hirst DG, 2009 Feb, Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells. J Gene Med, DOI: 10.1002/jgm.1280
McKeen HD, McAlpine K, Valentine A, Quinn DJ, McClelland K, Byrne C, O'Rourke M, Young S, Scott CJ, McCarthy HO, Hirst DG, Robson T, 2008 Nov, A novel FK506-like binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signaling. Endocrinology, DOI: 10.1210/en.2008-0168
McCarthy HO, Coulter JA, Robson T, Hirst DG, 2008 Aug, Gene therapy via inducible nitric oxide synthase: a tool for the treatment of a diverse range of pathological conditions. J Pharm Pharmacol, DOI: 10.1211/jpp.60.8.0007
Devlin AH, McIlroy M, McKeen HD, Bonde P, Menezes AA, Swarbrick CJ, Robson T, Hirst DG, Campbell FC, McGuigan JA, McKeown SR, 2009 Feb, Cytochrome P450 1B1 expression in rat esophageal tumorigenesis promoted by gastric and duodenal reflux. Mol Carcinog, DOI: 10.1002/mc.20459
Marignol L, Robson T, McCarthy HO, Worthington J, Murray MM, Hollywood D, Lawler M, Hirst DG, 2008 Sep, The tissue plasminogen activator gene promoter: a novel tool for radiogenic gene therapy of the prostate? J Gene Med, DOI: 10.1002/jgm.1221

Please visit PubMed for more information on Tracy Robson's publications

Funding Agency: NCRC - Paediatric Research Project Grants 2018
Project Title:Unravelling the role of FKBPL in Childhood Obesity
Start Date/End Date:Sept 2018 - Aug 2021
Total Awarded:€262,000
Funding Agency:Almac Discovery
Project Title:Mechanistic insights into the anti-stemness activity of FKBPL-based peptides
Start Date/End Date:January 2017 - January 2019
Total Awarded:£200,000
Funding Agency:Invest NI Proof of Concept
Project Title:Tackling obesity with a new nanomedicine
Start Date/End Date:September 2016 - Sept 2018
Total Awarded:£106,000
Funding Agency:Invest NI Proof of Concept
Project Title:A new pro-angiogenic nanomedicine for chronic wound healing
Start Date/End Date:September 2016 - Sept 2018
Total Awarded:£106,000
Name:Professor Tim Harrison
Position:Vice President Discovery Chemistry
Institution:Almac Discovery Ltd.
Country:Northern Ireland
Name:Professor Helen McCarthy
DepartmentChairperson Phion & Professor, School of Pharmacy, QUB
Institution:Phion Therapeutics
Country:Northern Ireland

    Honours & Awards

    2015    Winner, inaugural PG Supervisory Excellence Award, QUB

    2013    Nominated and shortlisted for the Vice Chancellors Impact Prize, QUB.

    2011    Nominated and shortlisted for the World Technology Awards, within the Health and Medicine section; these awards are for those individuals doing innovative work of “the greatest likely long-term significance” in their fields; those “creating the 21st century”.

    1999    The Lunn’s Award of Excellence. Sponsored by Lunn’s (Northern Ireland). In recognition of services to heath, wealth and wellbeing of the people of Northern Ireland.

    Professional Associations:

    2010-present   Fellow of the Royal Society of Biology (nominated Fellow)

    1997-present   Member of the Association for Radiation Research, UK (ARR)

    2008-present   Member of the European Association for Cancer Research (EACR)

    2002-present   Member of the Irish Association for Cancer Research (IACR)

    2007-present   Member of the Irish Radiation Research Society (IRRS)